[go: up one dir, main page]

AR079750A2 - Comprimidos bucodispersables y metodo de fabricacion - Google Patents

Comprimidos bucodispersables y metodo de fabricacion

Info

Publication number
AR079750A2
AR079750A2 ARP100104958A ARP100104958A AR079750A2 AR 079750 A2 AR079750 A2 AR 079750A2 AR P100104958 A ARP100104958 A AR P100104958A AR P100104958 A ARP100104958 A AR P100104958A AR 079750 A2 AR079750 A2 AR 079750A2
Authority
AR
Argentina
Prior art keywords
active pharmaceutical
pharmaceutical component
sponsible
tablets
manufacturing
Prior art date
Application number
ARP100104958A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR079750(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR079750A2 publication Critical patent/AR079750A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un comprimido bucodispersable que tiene una dureza de al menos 22 N y un tiempo de desintegracion bucal de menos de 120 seg y que comprende un componente farmacéutico activo que se adsorbe en un relleno hidrosoluble, uno o más desintegrantes y opcionalmente relleno hidrosoluble adicional, donde dicho componente farmacéutico activo tiene un punto de fusion en el rango de 40-100sC. Reivindicacion 3: Un comprimido bucodispersable de acuerdo con la reivindicacion 1 o 2, que se caracteriza en que el componente farmacéutico activo se selecciona del grupo que consiste en escitalopram, etosuximida, trimetadiona, clorambucilo, disulfiram, fenofibrato, guaifenesina, lomustina, carisoprodol y perfenacina.
ARP100104958A 2005-06-22 2010-12-27 Comprimidos bucodispersables y metodo de fabricacion AR079750A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500912 2005-06-22

Publications (1)

Publication Number Publication Date
AR079750A2 true AR079750A2 (es) 2012-02-15

Family

ID=37546630

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060102654A AR055062A1 (es) 2005-06-22 2006-06-21 Base cristalina de escitalopram y comprimidos bucodispersables que comprenden una base de escitalopram
ARP100104958A AR079750A2 (es) 2005-06-22 2010-12-27 Comprimidos bucodispersables y metodo de fabricacion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP060102654A AR055062A1 (es) 2005-06-22 2006-06-21 Base cristalina de escitalopram y comprimidos bucodispersables que comprenden una base de escitalopram

Country Status (39)

Country Link
EP (3) EP2385044A1 (es)
JP (5) JP4906852B2 (es)
KR (5) KR20120064140A (es)
CN (2) CN101928269A (es)
AR (2) AR055062A1 (es)
AT (3) ATE497500T1 (es)
AU (2) AU2006261452B2 (es)
BG (1) BG66086B1 (es)
BR (1) BRPI0612295A2 (es)
CA (2) CA2612827C (es)
CY (1) CY1112392T1 (es)
CZ (3) CZ299906B6 (es)
DE (2) DE602006019961D1 (es)
DK (3) DK1896439T4 (es)
EA (2) EA019239B1 (es)
EE (1) EE00773U1 (es)
ES (2) ES2356838T5 (es)
FI (2) FI20080548A7 (es)
GB (2) GB2448834B (es)
HR (1) HRP20110093T4 (es)
HU (1) HUP0800135A3 (es)
IL (1) IL187454A0 (es)
IS (1) IS8705A (es)
LT (1) LT5550B (es)
LV (1) LV13677B (es)
MX (1) MX2007015328A (es)
MY (2) MY143252A (es)
NO (2) NO20080359L (es)
PL (2) PL1896439T5 (es)
PT (1) PT1896439E (es)
RS (1) RS51575B2 (es)
SG (1) SG169358A1 (es)
SI (1) SI1896439T2 (es)
SK (1) SK500402007A3 (es)
TR (2) TR200708792T1 (es)
TW (2) TWI347942B (es)
UA (1) UA86536C2 (es)
WO (1) WO2006136169A2 (es)
ZA (2) ZA200711066B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
WO2008104880A2 (en) * 2007-03-01 2008-09-04 Aurobindo Pharma Limited Stable solid dosage forms of an antidepressant
SI2595979T1 (sl) 2010-07-23 2016-09-30 H. Lundbeck A/S Proces za čiščenje farmacevtsko sprejemljivih soli Escitaloprama
CN103360353A (zh) * 2013-08-07 2013-10-23 中国药科大学 草酸艾司西酞普兰杂质的制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
JP6423133B1 (ja) * 2017-04-10 2018-11-14 東和薬品株式会社 エスシタロプラム医薬組成物
CN110711198B (zh) * 2018-07-12 2022-03-15 山东大学 D-甘露糖在制备抗抑郁药物中的应用
KR102331187B1 (ko) 2019-04-09 2021-11-26 주식회사 라이트팜텍 에스시탈로프람을 함유하는 안정성이 우수한 경구용 액제 조성물 및 그의 제조방법
EP4277661A1 (en) * 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
JPH05222041A (ja) * 1992-02-13 1993-08-31 Mitsubishi Gas Chem Co Inc アデニン誘導体の精製法
AU680345B2 (en) * 1994-01-27 1997-07-24 Board Of Regents Of The University Of Oklahoma, The Rapidly dissolving oral dosage form
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
EP0993524B1 (en) 1997-06-30 2002-11-20 Beloit Technologies, Inc. Method and apparatus for the high speed application of coating to a traveling paper web
KR100357975B1 (ko) 1997-07-08 2002-10-25 하. 룬트벡 아크티에 셀스카브 시탈로프램의 제조방법
WO1998019512A2 (en) 1997-11-11 1998-05-14 H. Lundbeck A/S Method for the preparation of citalopram
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
US20020071864A1 (en) * 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ITMI991581A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
JP2001226372A (ja) * 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
EP1334716A4 (en) * 2000-10-16 2009-04-29 Daiichi Seiyaku Co MEDICAL COMPOSITIONS THAT CAN RAPIDLY DISINTEGRATE IN ORAL CAVITY AND METHOD OF PRODUCING THE SAME
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
EP1181713B1 (en) * 2000-12-22 2004-09-29 H. Lundbeck A/S Method for the preparation of pure citalopram
DE60100016T2 (de) * 2000-12-28 2003-04-17 H. Lundbeck A/S, Valby Verfahren zur herstellung von reinem citalopram
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US6872405B2 (en) * 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
GB0113842D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
ATE286730T1 (de) * 2001-07-31 2005-01-15 Lundbeck & Co As H Kristalline zusammensetzung mit escitalopram
IS7239A (is) 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
WO2003057132A2 (en) * 2002-01-07 2003-07-17 Sun Pharmaceutical Industries Limited Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
EP1517676A1 (en) * 2002-05-03 2005-03-30 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
BR0317623A (pt) 2002-12-23 2005-11-29 Lundbeck & Co As H Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
CN1510024A (zh) * 2002-12-24 2004-07-07 北京德众万全药物技术开发有限公司 可用于制备西酞普兰(s)-对映异构体的新的化合物及其制备方法
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
CA2524806C (en) * 2003-05-07 2011-07-12 Akina, Inc. Highly plastic granules for making fast melting tablets
EP1674083B1 (en) * 2003-10-15 2018-08-01 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
WO2005049596A1 (en) * 2003-11-20 2005-06-02 Natco Pharma Limited A process for the preparation of high purity escitalopram
HU227491B1 (en) * 2003-11-25 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Tablet containing citalopram hydrogen bromide
WO2005084643A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
WO2006106531A1 (en) * 2005-04-04 2006-10-12 Jubilant Organosys Ltd Process for the preparation of escitalopram or its acid addition salts

Also Published As

Publication number Publication date
TW201130808A (en) 2011-09-16
JP2012072168A (ja) 2012-04-12
PL1896439T3 (pl) 2011-04-29
EP2325177A1 (en) 2011-05-25
FI20080548L (fi) 2008-10-07
JP2009179635A (ja) 2009-08-13
KR20100133023A (ko) 2010-12-20
SI1896439T2 (sl) 2014-12-31
SG169358A1 (en) 2011-03-30
EA200800102A1 (ru) 2008-04-28
DK200900284A (da) 2009-02-27
AT11883U1 (de) 2011-06-15
ZA200901698B (en) 2010-04-28
JP4415056B2 (ja) 2010-02-17
DK1896439T3 (da) 2011-02-28
LT2008005A (en) 2008-10-27
PL1896439T5 (pl) 2016-01-29
SI1896439T1 (sl) 2011-03-31
MY143239A (en) 2011-04-15
PL384185A1 (pl) 2008-06-23
GB0724557D0 (en) 2008-01-23
PT1896439E (pt) 2011-02-15
AU2010200844A1 (en) 2010-04-01
MY143252A (en) 2011-04-15
ES2319073A1 (es) 2009-05-01
AU2006261452A1 (en) 2006-12-28
CA2646780A1 (en) 2006-12-28
ZA200711066B (en) 2009-07-29
HUP0800135A3 (en) 2009-01-28
TWI358407B (en) 2012-02-21
WO2006136169A3 (en) 2007-10-18
HUP0800135A2 (en) 2008-06-30
UA86536C2 (ru) 2009-04-27
MX2007015328A (es) 2008-02-15
EP2385044A1 (en) 2011-11-09
LV13677B (en) 2008-05-20
CY1112392T1 (el) 2015-12-09
JP5731957B2 (ja) 2015-06-10
LT5550B (lt) 2009-03-25
AU2006261452B2 (en) 2010-02-04
FI20077133L (fi) 2007-12-20
GB2448834B (en) 2010-01-20
HRP20110093T1 (hr) 2011-03-31
CZ2007898A3 (cs) 2008-01-23
GB0811164D0 (en) 2008-07-23
DE112006001619T5 (de) 2008-06-12
JP4906852B2 (ja) 2012-03-28
CZ299906B6 (cs) 2008-12-29
CZ301286B6 (cs) 2009-12-30
TR200708792T1 (tr) 2008-05-21
TW200740785A (en) 2007-11-01
AT10983U1 (de) 2010-02-15
TR201000625T1 (tr) 2010-03-22
EP1896439A2 (en) 2008-03-12
FI20077133A7 (fi) 2007-12-20
KR20110033310A (ko) 2011-03-30
CN101928269A (zh) 2010-12-29
ES2356838T3 (es) 2011-04-13
BRPI0612295A2 (pt) 2011-01-04
FI20080548A7 (fi) 2008-10-07
EE00773U1 (et) 2008-10-15
EP1896439B2 (en) 2014-10-15
EA201001108A1 (ru) 2011-02-28
ES2356838T5 (es) 2015-01-26
CA2612827C (en) 2010-11-30
KR101340815B1 (ko) 2013-12-11
DE602006019961D1 (de) 2011-03-17
RS51575B2 (sr) 2018-02-28
EP1896439B1 (en) 2011-02-02
BG66086B1 (bg) 2011-03-31
IL187454A0 (en) 2008-02-09
CA2612827A1 (en) 2006-12-28
AR055062A1 (es) 2007-08-01
JP2008546724A (ja) 2008-12-25
ATE497500T1 (de) 2011-02-15
DK1896439T4 (en) 2015-01-12
GB2442160B (en) 2010-01-20
CN101189220A (zh) 2008-05-28
ES2319073B1 (es) 2010-02-26
BG110024A (bg) 2008-05-30
NO20101777L (no) 2008-01-18
EA019239B1 (ru) 2014-02-28
WO2006136169A2 (en) 2006-12-28
KR20110084341A (ko) 2011-07-21
NO20080359L (no) 2008-01-18
HRP20110093T4 (hr) 2015-02-27
GB2448834A (en) 2008-10-29
KR20120064140A (ko) 2012-06-18
JP2009046506A (ja) 2009-03-05
CZ300686B6 (cs) 2009-07-15
KR20080018191A (ko) 2008-02-27
TWI347942B (en) 2011-09-01
RS51575B (sr) 2011-08-31
DK200800075A (da) 2008-03-15
SK500402007A3 (sk) 2008-05-06
JP2009179634A (ja) 2009-08-13
GB2442160A (en) 2008-03-26
IS8705A (is) 2008-01-14

Similar Documents

Publication Publication Date Title
AR079750A2 (es) Comprimidos bucodispersables y metodo de fabricacion
IN2012DN00570A (es)
ECSP088239A (es) Composición de liberación de fármaco sostenida
MX2010008138A (es) Forma de dosis farmaceutica.
AR063606A1 (es) Estabilizacion de vacunas mediante liofilizacion
MX374694B (es) USO DE 1-CLORO-4-(ß-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO EN COMBINACIÓN CON INSULINA PARA REDUCIR LA DOSIS DE INSULINA Y PARA MEJORAR EL CONTROL GLUCÉMICO EN PACIENTES CON DIABETES MELLITUS.
AR053466A1 (es) Un sistema de suministro para componentes activos como parte de una composicion comestible que incluye una relacion de material encapsulante y componente activo
MY157683A (en) Combination product for controlling parasites on animals
CL2007002331A1 (es) Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih.
CL2007003722A1 (es) Compuestos derivados de propionamida n-sustituida por heterociclo, activadores de glucoquinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento o prevencion de la diabetes.
HN2008001652A (es) Compuesto y composiciones como modulares de la senda de hedgehog
NO20075927L (no) IL-21 varianter
EP2647692A3 (en) Compositions and methods comprising serine protease variants
CO6160335A2 (es) Vacuna
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
WO2011015744A3 (fr) Composition injectable associant un agent de comblement et un milieu de croissance des fibroblastes
PH12012501811A1 (en) A solid pharmaceutical dosage formulation
MY165889A (en) Compositions and methods of using proislet peptides and analogs thereof
AR053464A1 (es) Un sistema de suministro para componenetes activos y un material que tiene hidrofobicidad preseleccionada comoparte de una composicion comestible
ATE554742T1 (de) Hydrophilisierte härtbare silikonabdruckmaterialien mit verbessertem lagerverhalten
AR064613A1 (es) Composicion para controlar parasitos en animales
MY152388A (en) Composition and method for controlling plant diseases
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions
ES2526968T3 (es) Una composición agrícola, método para su producción y usos en el tratamiento de cultivos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal